MRD-Guided Ibrutinib Plus Venetoclax Therapy for CLL
June 9, 2025
MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.
MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911